Vaxart Analyst Ratings
Vaxart Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/02/2022 | 153.97% | Cantor Fitzgerald | $11 → $8 | Maintains | Overweight |
05/19/2022 | 90.48% | B. Riley Securities | $7 → $6 | Maintains | Neutral |
11/02/2021 | 376.19% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
06/30/2021 | 185.71% | B. Riley Securities | $13 → $9 | Downgrades | Buy → Neutral |
06/24/2021 | 312.7% | Jefferies | → $13 | Initiates Coverage On | → Buy |
06/11/2021 | 471.43% | Piper Sandler | → $18 | Initiates Coverage On | → Overweight |
08/12/2020 | 439.68% | HC Wainwright & Co. | $7 → $17 | Maintains | Buy |
07/13/2020 | 598.41% | B. Riley Securities | → $22 | Initiates Coverage On | → Buy |
04/30/2020 | 122.22% | HC Wainwright & Co. | $3 → $7 | Reiterates | → Buy |
06/27/2019 | -36.51% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
09/02/2022 | 153.97% | 坎托·菲茨杰拉德 | 11 美元 → 8 美元 | 维护 | 超重 |
05/19/2022 | 90.48% | B. 莱利证券 | 7 美元 → 6 美元 | 维护 | 中立 |
11/02/2021 | 376.19% | 坎托·菲茨杰拉德 | → 15 美元 | 启动覆盖范围开启 | → 超重 |
2021 年 6 月 30 日 | 185.71% | B. 莱利证券 | 13 美元 → 9 美元 | 降级 | 买入 → 中性 |
2021 年 6 月 24 日 | 312.7% | 杰富瑞集团 | → 13 美元 | 启动覆盖范围开启 | → 购买 |
06/11/2021 | 471.43% | 派珀·桑德勒 | → 18 美元 | 启动覆盖范围开启 | → 超重 |
08/12/2020 | 439.68% | HC Wainwright & Co. | 7 美元 → 17 美元 | 维护 | 买 |
07/13/2020 | 598.41% | B. 莱利证券 | → 22 美元 | 启动覆盖范围开启 | → 购买 |
04/30/2020 | 122.22% | HC Wainwright & Co. | 3 美元 → 7 美元 | 重申 | → 购买 |
06/27/2019 | -36.51% | HC Wainwright & Co. | → 2 美元 | 启动覆盖范围开启 | → 购买 |
Vaxart Questions & Answers
Vaxart 问题与解答
The latest price target for Vaxart (NASDAQ: VXRT) was reported by Cantor Fitzgerald on September 2, 2022. The analyst firm set a price target for $8.00 expecting VXRT to rise to within 12 months (a possible 153.97% upside). 3 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2022年9月2日公布了Vaxart(纳斯达克股票代码:VXRT)的最新目标股价。该分析公司将目标股价定为8.00美元,预计VXRT将在12个月内升至12个月内(可能上涨153.97%)。去年有3家分析公司公布了评级。
The latest analyst rating for Vaxart (NASDAQ: VXRT) was provided by Cantor Fitzgerald, and Vaxart maintained their overweight rating.
Vaxart(纳斯达克股票代码:VXRT)的最新分析师评级由坎托·菲茨杰拉德提供,Vaxart维持增持评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vaxart, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vaxart was filed on September 2, 2022 so you should expect the next rating to be made available sometime around September 2, 2023.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Vaxart的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Vaxart的最新评级是在2022年9月2日发布的,因此您应该预计下一个评级将在2023年9月2日左右公布。
While ratings are subjective and will change, the latest Vaxart (VXRT) rating was a maintained with a price target of $11.00 to $8.00. The current price Vaxart (VXRT) is trading at is $3.15, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Vaxart(VXRT)评级保持不变,目标股价为11.00美元至8.00美元。Vaxart(VXRT)目前的交易价格为3.15美元,超出了分析师的预期区间。